REHOVOT, Israel, Jan. 18, 2021 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage firm advancing first-in-class therapies to beat tumor immune evasion and drug resistance, immediately introduced that the Purple Biotech administration workforce will current a company overview on the B. Riley Oncology Investor Convention, being held nearly January 20-21, 2021.
Date: Wednesday, January 20
Time: 10:30 AM ET
Webcast: A reside webcast of the presentation can be obtainable on the investor part of the Purple Biotech web site at www.purple-biotech.com. Following the reside webcast, the occasion will stay archived on the Purple Biotech’s web site for about 90 days.
About Purple Biotech
Purple Biotech Ltd. (the “Company”; NASDAQ/TASE: PPBT) is a clinical-stage firm specializing in advancing first-in-class therapies to beat tumor immune evasion and drug resistance so as to create profitable long-lasting therapies for individuals with most cancers. The Firm’s oncology pipeline consists of NT219 and CM24. NT219 is a small molecule focusing on the novel most cancers drug resistance pathways IRS1/2 and STAT3. The Firm is at present advancing NT219 as a monotherapy therapy of superior stable tumors and together with cetuximab for the therapy of recurrent or metastatic squamous cell carcinoma of head and neck most cancers (SCCHN) in a part half research. CM24 is a monoclonal antibody blocking CEACAM1, a novel immune checkpoint that helps tumor immune evasion and survival by way of a number of pathways. The Firm plans to advance CM24 as a mixture remedy with anti-PD-1 checkpoint inhibitors in chosen most cancers indications in a part 1 research adopted by a part 2 for the therapy of non-small cell lung most cancers and pancreatic most cancers. The Firm has entered right into a scientific collaboration settlement, as amended, with Bristol Myers Squibb for the deliberate part half scientific trials to judge the mix of CM24 with the PD-1 inhibitor nivolumab (Opdivo®) in sufferers with non-small cell lung most cancers and together with nivolumab along with nab-paclitaxel (ABRAXANE®) in sufferers with pancreatic most cancers. The Firm can be the proprietor of Consensi®, a fixed-dose mixture of celecoxib and amlodipine besylate, for the simultaneous therapy of osteoarthritis ache and hypertension that was authorized by the FDA for advertising and marketing within the U.S. Consensi® is being bought within the U.S. by Burke Therapeutics, the advertising and marketing associate of the Firm’s U.S. distributor, Coeptis Prescription drugs. The Firm has additionally partnered to commercialize Consensi in China and South Korea. The Firm has lately relocated its company headquarters to Rehovot, Israel. For extra info, please go to http://www.purple-biotech.com.
Deputy CEO & Chief Monetary Officer
Investor Relations Contact: